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Abstract
Osteogenic behaviour of osteoblasts from trabecular, 
cortical and subchondral bone were examined to determine 
any bone type-selective differences in samples from 
both osteoarthritic (OA) and osteoporotic (OP) patients. 
Cell growth, differentiation; alkaline phosphatase 
(TNAP) mRNA and activity, Runt-related transcription 
factor-2 (RUNX2), SP7-transcription factor (SP7), bone 
sialoprotein-II (BSP-II), osteocalcin/bone gamma-
carboxyglutamate (BGLAP), osteoprotegerin (OPG, 
TNFRSF11B), receptor activator of nuclear factor-κβ ligand 
(RANKL, TNFSF11) mRNA levels and proangiogenic 
vascular endothelial growth factor-A (VEGF-A) mRNA and 
protein release were assessed in osteoblasts from paired 
humeral head samples from age-matched, human OA/OP 
(n = 5/4) patients. Initial outgrowth and increase in cell 
number were significantly faster (p < 0.01) in subchondral 
and cortical than trabecular osteoblasts, in OA and OP, and 
this bone type-related differences were conserved despite 
consistently faster growth in OA. RUNX2/SP7 levels and 
TNAP mRNA and protein activity were, however, greater 
in trabecular than subchondral and cortical osteoblasts 
in OA and OP. BSP-II levels were significantly greater 
in trabecular and lowest in cortical osteoblasts in both 
OA and OP. In contrast, BGLAP levels showed divergent 
bone type-selective behaviour; highest in osteoblasts 
from subchondral origins in OA and trabecular origins 
in OP. We found virtually identical bone type-related 
differences, however, in TNFRSF11B:TNFSF11 in OA and 
OP, consistent with greater potential for paracrine effects 
on osteoclasts in trabecular osteoblasts. Subchondral 
osteoblasts (OA) exhibited highest VEGF-A mRNA levels 
and release. Our data indicate that human osteoblasts in 
trabecular, subchondral and cortical bone have inherent, 
programmed diversity, with specific bone type-related 
differences in growth, differentiation and pro-angiogenic 
potential in vitro.
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Introduction
Osteoblasts isolated from diverse anatomical sites have 
been used to study bone cell behaviour in vitro. Thus, 
calvarial- and long bone-derived cells from rodents 
are very common model systems. Cells with disparate 
origins, such as trabecular and cortical bone, are also used 
somewhat interchangeably, to inform understanding of 
skeletal biology. Although all bone exhibits some highly 
conserved factors in its development, remodelling and 
repair, it is also apparent that the response to many in vivo 
challenges is not always identical in trabecular, cortical 
and subchondral bones types (Lavigne et al., 2005; Simon 
et al., 2008; Wade-Gueye et al., 2010). Differences in 
osteoblasts derived from long bone and calvarial sites, 
including distinct transcriptional signatures, have been 
described in vitro (Akintoye et al., 2006; Rawlinson et 
al., 2009). Solchaga and colleagues have described the 
difference in osteogenic potential in cells from the same 
bone, however originating from different anatomical 
locations such as marrow and periosteum in rabbit tibia 
(Solchaga et al., 1998). Furthermore, within the same 
bone structure, osteoblasts display differential gene 
transcriptions depending on their anatomical location 
(Candeliere et al., 2001). Cell preparations from trabecular, 
cortical and subchondral bone types have not yet, however, 
been extensively compared in parallel assays and it remains 
possible that bone cell behaviour in these diverse bone 
types may be underpinned by the origins and performance 
of local osteoblasts. It is also possible that sampling and 
assessment of cells from one particular bone type might 
obscure or conceal differences in osteoblasts, when 
comparing disease states.
 The trabecular bone is located mainly in the metaphysis 
and extremities of long bones and comprises of structures 
and architectures that differ markedly from those 
found in the cortical or subchondral bone. Despite 
constituting a relatively small fraction of total bone 
volume, organisational alignment of bone structures in 
this trabecular compartment normally produces robust 
load-bearing and much of the total bone surface area for 
remodelling (Lanyon, 1984). Trabecular bone is also more 
porous and less dense than cortical bone, and supplies most 
of the exchangeable pool of calcium. It is thought that 
this large surface area contributes to a higher metabolic 
remodelling activity compared to cortical bone (Aerssens 
et al., 1997). These comparisons illustrate the differing 
functions of bone that exist even within a single anatomical 
location in these structurally diverse compartments, and 
it is clear that they also differ in how they are affected by 
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metabolic challenges, vascular influences or diseases, such 
as osteoarthritis (OA) and osteoporosis (OP).
 These distinct types of bone compartment are affected 
differently in OA and OP, and both diseases are also strongly 
influenced by age and metabolism, and by mechanical 
load-related and inheritable genetic factors (Aerssens et 
al., 1997; Bultink and Lems, 2013; Lories and Luyten, 
2012; Richards et al., 2012). OA progression involves 
cartilage degradation, synovium and tendon inflammation, 
osteophyte formation and a characteristic thickening of the 
subchondral bone plate (Li et al., 1999). This subchondral 
bone thickening is thought to have mechanical origins 
and may also be associated with emerging genetics, 
such as GDF5 (encoding growth differentiation factor 5) 
polymorphisms that have been linked with OA (Dodd et al., 
2012). The diminished bone mass and microarchitecture 
deterioration in OP is likely linked to dysfunctional 
mechanoadaptive responses or, for example, variants of 
multiple genes associated with bone mineral density such 
as VDR (encoding vitamin D receptor), PTH1R (encoding 
PTH receptor 1), RANK-RANKL-OPG, oestrogen and 
Wnt signalling pathways (Estrada et al., 2012; Kanis 
and Johnell, 2011). The relationship between OA and 
OP is debated (Dequeker et al., 1975; Jiang et al., 2008; 
Pervaiz et al., 2013; Verstraeten et al., 1991). It is clear, 
nevertheless, that bone in the trabecular compartment 
in OP patients has lower strength and is of poor quality, 
whereas sclerotic, stiffer bone is found in the subchondral 
trabecular compartment in OA. These increases in stiffness 
of OA bone are not however necessarily correlated with 
strength. Indeed, Ding et al. (Ding et al., 2002) reported 
that the subchondral thickness is significantly increased 
in early OA but that it remains weaker than bone in 
healthy patients. For these reasons, comparisons between 
trabecular-, cortical- and subchondral-derived osteoblasts 
in distinct OA and OP patient groups will likely reveal any 
conserved bone type-selective behaviours of osteoblasts 
isolated from these different compartments. Conversely, 
any disease related differences that are conserved in all 
bone types in either OA or OP osteoblasts might provide 
novel insight into the underpinning disease mechanisms.
 Most studies using isolated primary human osteoblasts 
have not regarded the possibility that their site of origin 
from within a bone may influence behaviour. We have 
explored the hypotheses that osteoblasts derived from 
subchondral, cortical and trabecular bone types (from OA 
patients) exhibit differing osteogenic potential, and that 
these regional differences will persist even in samples 
from OP patients where osteogenic potential of isolated 
osteoblasts will be diminished. Using osteoblasts derived 
from these different bone types within a singular skeletal 
element, namely the head of the human humerus from OA 
and OP patients undergoing shoulder replacement surgery, 
our studies find that osteoblasts from OP patients exhibit a 
lesser osteogenic potential. Consistent with our hypothesis, 
we also find, however, a preservation of divergent growth 
dynamics, differentiation potential and modified pro-
angiogenic activity in osteoblasts derived from trabecular, 
cortical and subchondral bone types. Divergent osteogenic 
and angiogenic potentials of bone cells from the different 
bone types could influence the design and selection of 
future orthopaedic implants in the human shoulder, and 
perhaps more broadly, such that they achieve improved 
osseo-integration and thus limit complications, such as 
prosthetic loosening, gleno-humeral instability and peri-
prosthetic fracture (Bohsali et al., 2006).
Materials and Methods
Patients and sample preparation
Paired subchondral, trabecular and cortical bone samples 
were obtained intra-operatively from nine consecutive 
female patients during open total shoulder replacements 
or hemiarthroplasties. There were five female OA (mean 
age, 74 years; range 72-81 years) and four female OP 
patients (mean age, 80 years; range 73-86 years) selected 
by NHS clinical guidelines. None of these OP patients were 
suffering from vitamin D deficiency or renal disease and 
none were receiving cortisone treatment. All OP patients 
had received bisphosphonate treatment and dietary calcium 
supplements. Our supplementary studies used the rare 
opportunity to make comparison with paired subchondral, 
trabecular and cortical bone samples from one ‘normal’ 
female patient (30 years of age, undergoing humeral 
metaphyseal metastasis resection) without osteoarthritis 
or osteoporosis (Royal National Orthopaedic Hospital). 
Informed consent was obtained preoperatively from each 
patient in accordance with the approval from the Ethical 
Committees of Imperial NHS trust and Royal National 
Orthopaedic Hospital Biobank regulations in compliance 
with the United Kingdom Human Tissues Act 2004. Bone 
samples were collected under aseptic conditions in separate 
containers and transported from the operating theatre in 
sterile phosphate-buffered saline (PBS).
Preparation of explants and subchondral, trabecular 
and cortical bone primary osteoblasts
Separate explant cultures were prepared from subchondral 
(Hilal et al., 1998), trabecular (Taylor et al., 2014) 
and cortical bone samples taken from fixed anatomical 
locations from each patient during surgery (Fig.1). 
Subchondral bone was prepared by removing overlaying 
cartilage from the resected humeral head using a scalpel, 
followed by removal of trabecular bone from beneath 
using bone-cutters and rongeurs. This produces multiple 
~ 2 mm thick subchondral bone plate fragments, from 
which trabecular remnants were removed using a scalpel 
and scissors, that were subsequently dissected into ~ 1 mm3 
pieces. Trabecular bone from the humeral metaphysis was 
cut into ~ 1 mm3 chips and cleared of superficial marrow 
and fat by extensive agitation in PBS. Cortical bone, 
obtained by rongeur from the proximal humerus, was 
cleared of adherent marrow by scalpel, cut into ~ 1 mm3 
chips using a bone cutter and washed by extensive PBS 
agitation. In all three cases, dissected segments were then 
placed in sterile PBS.
 These bone chips were used to establish explant cultures 
(multiple ~ 1 mm3 bone chips (~ 20-30) in each flask 
(typically 2 flasks) for each bone type from each patient) 
to facilitate osteoblast outgrowth as previously described 
(Beresford et al., 1993; Clarkin et al., 2008a; Clarkin et 
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al., 2008b; Couchourel et al., 2009; Dillon et al., 2012; 
Gallagher et al., 1996; Grigoriadis et al., 1988; Hilal et 
al., 1998; Jagodzinski et al., 2004; Kwan Tat et al., 2010; 
Lajeunesse, 2002; Oshina et al., 2007; Rawlinson et al., 
1995; Rawlinson et al., 2009; Siggelkow et al., 1999; 
Simon et al., 2008; Taylor et al., 2014; Wong et al., 1990). 
Briefly, to restrict the number of non-bone contaminating 
cells the bone segments were washed with PBS containing 
10 % antibiotic-antimycotic (AB/AM) (Invitrogen, 
Paisley, UK)) six times by vortexing and transferred into 
appropriately labelled 7 mL bijous tubes containing 0.25 % 
trypsin- trypsin/ethylenediaminetetraacetic acid (EDTA) 
(Invitrogen, Paisley, UK) and placed in a shaking water 
bath at 37° C for 10 min. After a brief wash in PBS, the 
segments were incubated with 1 % type II collagenase 
from Clostridium histolyticum (Sigma Aldrich, Dorset, 
UK) for 30 min in a shaking water bath at 37° C to remove 
contaminating surface marrow cells. The bone chips 
were washed three times in sterile PBS containing 10 % 
antibiotic-antimycotics, then placed into 75 mm2 tissue 
culture flasks (NUNC, UK) with Dulbecco’s minimal 
essential medium (DMEM; without phenol red, containing 
sodium pyruvate and 1 g/L d-glucose; (Invitrogen, 
Paisley, United Kingdom)) supplemented with 10 % heat-
inactivated foetal bovine serum (Invitrogen, Paisley, United 
Kingdom), 2 mM L-glutamine, 100 U/mL of penicillin, 
100 mg/mL of streptomycin and 0.25 µg/mL Amphotericin) 
and maintained in a humidified incubator at 37° C for 6-8 
weeks to allow cellular outgrowth with media changes 
every week. Cells were observed growing out the explant 
after 7 days. Explant cultures (for each bone type in each 
patient) were prepared for subsequent analysis (see below) 
and cell outgrowth (% confluence) was monitored daily 
using a grid system placed under each culture flask to assess 
the number of days taken to produce 85 % cell coverage 
of the total grid surface (expressed as 1/number of days 
taken). Having reached 85 % confluence, each of these 
cultures were first washed with PBS and the remaining 
bone chips discarded, then Accutase™ (Invitrogen, Paisley, 
UK)-digested, replicate flasks (typically 2) pooled and sub-
seeded in a range of formats described below, with media 
changes performed every 2 days, for subsequent analyses 
in which only passage 1 cells were used. In the case of the 
single set of rare normal samples, explants of each bone 
type were re-cultured three times following confluence to 
establish new replicate independent cultures (e.g. E1, E2, 
E3) as described elsewhere (Gartland et al., 2012).
Cell number and viability
Prior studies have shown four-fold increase in human 
osteoblast numbers between 1-10 days of culture 
(Siggelkow et al., 1999). Crystal violet viability test was 
employed based on the inability of dead cells to remain 
adherent to cell culture plastic (McDonald et al., 2013; 
Sohaskey et al., 2010; Vora et al., 2010). Briefly, cells 
derived from subchondral, trabecular and cortical bone 
explants were sub-seeded at 2,000 cells/well into 48-well 
plates in basal media and maintained for 10 days before 
assessment of cell number and viability (triplicates for 
each bone type from each patient). After 10 days, cells 
were washed three times with PBS and fixed in 4 % 
para-formaldehyde (PFA) (Sigma Aldrich, Dorset, UK). 
Monolayers of attached cells were then stained with 
0.1 % crystal violet dye in distilled H2O for 30 min for 
DNA. Excess dye was removed and cells thoroughly 
washed and bound stain subsequently eluted from cells 
using 10 % acetic acid. The quantity of eluted stain was 
measured at 595 nm using a 96-well microtitre plate reader. 
A standard curve was prepared with known serial dilutions 
of stained cells from which and the total numbers of DAPI 
(Invitrogen, Paisley, United Kingdom) positive cells in the 
experiments were extrapolated.
Alkaline phosphatase activity (TNAP) assay and 
staining
Osteoblasts derived from subchondral, trabecular, and 
cortical human bone were sub-seeded at 20,000 cells/well 
in 24-well plates in triplicate per patient and maintained in 
basal medium with half media changes on alternate days 
until confluent (typically 15 days for subchondral and 
cortical, and 21 days for trabecular osteoblasts). Cells were 
then incubated in either basal medium or basal medium 
supplemented with β-glycerophosphate (2 mM), ascorbate-
2-phosphate (50 μg/mL) and a synthetic glucocorticoid 
(10 nM dexamethasone, Sigma, Dorset, UK (referred to 
as osteogenic medium, + OM herein) for 36 days prior to 
assessment of TNAP activity (triplicates for each bone 
type from each patient).
 Total TNAP activity was assessed in cell lysates from 
individual wells by a method modified from that described 
by Lowry et al. and Shah et al. (Lowry et al., 1954; Shah et 
al., 2010). Briefly, cells were rinsed three times with PBS, 
digested with 0.1 % Triton X-100, scraped off the plate 
and the cell suspension sonicated (Ultrasonic disintegrator, 
MSE laboratories, Butte, MT). Briefly, enzyme activity 
in half of total volume of these cell lysates was measured 
in assay buffer containing 0.1 M diethanolamine, 1 mM 
Fig. 1. Cross-sectional schematic illustration of a Human 
gleno-humeral joint depicting different anatomical bone 
types. The different bone types from which the samples 
were obtained for the current study are highlighted in 
the black boxes. Figure purchased from Netter Images 
(Elsevier: www.netterimages.com).
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MgCl2 and 2 mM p-nitrophenylphosphate (Sigma Aldrich, 
Dorset, UK) pH 10.5 added to cell homogenates. A 
standard curve was prepared with p-nitrophenol solutions. 
Incubation of standards and samples was performed at 
37° C for 5 min and the reaction stopped by adding 0.3 M 
NaOH. Reaction mixtures were transferred into 96-well 
plates and absorbance measured at 410 nm. A fraction 
of the lysate was also used to measure protein content 
with the bicinchoninic acid (BCA) assay reagent (Pierce, 
Rockford, IL) and the relative TNAP activity was defined 
as nanomoles of p-nitrophenol phosphate hydrolysed /min/
mg of total protein. TNAP activity was also visualised by 
histochemical staining in additional wells using naphthol 
AS-TR (Sigma Aldrich, Dorset, UK) as a substrate and 
Fast blue to produce a coloured precipitate, as previously 
described (Shah et al., 2010). Stained wells were imaged 
using a high-resolution flatbed scanner.
RNA isolation
Human osteoblasts from each of the patient-matched 
bone types were sub-seeded at 20,000 cells/well in basal 
medium in 24-well plates in triplicate and maintained 
until confluent (see above), at which point total RNA was 
collected for gene expression analysis (in triplicate). For 
TNAP mRNA expression analysis, total RNA was collected 
24 h; 7 d and 14 d post confluence. Medium was removed 
and the monolayers were agitated and lysed with 200 μL 
Qiazol (Qiagen, UK) using a cell scraper. The lysates 
were transferred into clean microcentrifuge tubes and 
homogenised by passing through a 23 g sterile needle and 
200 μL of 100 % ethanol added. The homogenates were 
then vortexed 3 times for 5 s. Total cellular RNA was 
isolated from the homogenates using the Direct-Zol™ 
miniprep kit (Zymoresearch, Cedarlanelabs, Canada) 
according to the manufacturer’s instructions. RNA integrity 
was established by gel electrophoresis and RNA purity by 
nanodrop spectroscopy (NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (Thermo Scientific, UK)). Acceptable 
samples displayed two clear ribosomal bands (indicating 
no degradation had occurred during isolation), 260/280 
ratios > 2.0 and 260/230 ratios > 1.8 (Hildyard and Wells, 
2014; Nolan et al., 2006).
cDNA synthesis and Real Time Quantitative PCR
Reverse transcription was performed on triplicate 200 ng 
samples of total RNA (20 μL reaction volume) using a 
high-capacity RNA-to-complementary DNA (cDNA) kit 
(Applied Biosystems (Invitrogen, Paisley, UK)) run at 
37° C for 60 min and at 85° C for 5 min (Poulet et al., 2012). 
To detect messenger RNA (mRNA) transcripts, primers 
(designed using Primer3 Plus (Galea et al., 2013; Rozen 
and Skaletsky, 2000) (see Table 1 for details)) were pre-
mixed with SYBR Green JumpStart Taq ReadyMix (Sigma 
Aldrich, Dorset, UK), and 10 μL aliquots were applied 
to 384-well optical plates (white hard-shell thin-walled) 
Bio-Rad Biorad, Herts, UK), The 1:4 diluted cDNA were 
applied in triplicate in 2 μL aliquots such that each plate 
consisted matching subchondral, trabecular and cortical 
bone samples from all patients (in triplicate). Thermal 
cycling conditions were as follows: 10 min at 95° C, with 40 
cycles of 15 s at 95° C, 30 s at 60° C, and 20 s at 72° C, on a 
Bio-Rad CFX384 Real-Time System. Dilution series were 
Table 1. List of Primers used for qPCR. (a) (Atkins et al., 2011) and (b) (Kiselak et al., 2010).
NCBI Reference Details Gene ID  Primer Sequence 5’ - 3’
NM_001024630.3 Runt related transcription factor 2 (RUNX2) RUNX-2 
Forward GGAGTGGACGAGGCAAGAGTTT
Reverse AGCTTCTGTCTGTGCCTTCTGG
NM_001173467.1 Osterix SP7
Forward TGGACATGACACACCCCTATG
Reverse CCACCACCTAGCCAGTTGC
NM_004967.3 Bone Sialoprotein-II BSP-II 
Forward GAACCTCGTGGGGACAATTAC
Reverse CATCATAGCCATCGTAGCCTTG
NM_199173.4 Osteocalcin BGLAP 
Forward CTTTGTGTCCAAGCAGGAGG
Reverse CTGAAAGCCGATGTGGTCAG
NM_001025366.2 Vascular endothelial growth factor-A VEGF-A 
Forward CACTGAGGAGTCCAACATACC
Reverse CTGCATTCACATTTGTTGTC
NM_003701.3
Receptor activator of 
nuclear factor kappa-B 
ligand (RANKL)
TNFSF11 
Forward CCAGGTTGTCTGCAGCGT
Reverse TGCAGTGAGTGCCATCTTCT
NM_002546.3 Osteoprotegerin (OPG) TNFRSF11B 
Forward GCAACACAGCTCACAAGAAC
Reverse GAAGGTGAGGTTAGCATGTCC
NM_000478.4 Alkaline phosphatase TNAP (a) 
Forward TGCTCCCACGCGCTTGTGCCTGGA
Reverse CTGGCACTAAGGAGTTAGTAAG
 NR_003286.2 18s  rRNA 18s  rRNA (b)
Forward GGCCCTGTAATTGGAATGAGTC
Reverse CCAAGATCCAACTACGAGCTT
NM_004048.2 β2-Microglobulin B2M 
Forward AGCAAGGACTGGTCTTTCTATCTC
Reverse CATGTCTCGATCCCACTTAACTATC
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used to establish that residual cDNA synthesis reagents 
did not impair PCR efficiency and each run consisted of 
melt curve analysis and template-free controls to confirm 
specific, single product amplification. All primer pairs 
produced single amplicons and reactions were of similar 
efficiency (95-100 %), as established by standard dilution 
curve and analysis. Target gene quantification was achieved 
using the 2-ΔΔCT method described by Livak et al. (Livak 
and Schmittgen, 2001) adapted from Pfafll (Pfaffl, 2001) 
relative to the ratio of β2-microglobulin (B2M): 18s rRNA 
(18s) which were chosen against a panel of housekeeping 
genes; β-actin, cyclophillinA and GAPDH using GeNorm 
software to determine the most stable housekeeping gene 
(http://medgen.ugent.be/~jvdesomp/genorm/) by making 
pairwise comparison to rank candidate genes by summed 
individual variation, discarding the most variant before 
repeating pairwise analysis to identify β2-microglobulin 
and 18s rRNA genes with minimum respective variation 
(Bustin et al., 2009; Hildyard and Wells, 2014; Nolan et 
al., 2006).
Quantification of Vascular Endothelial Growth 
Factor-A165 protein release
Human osteoblasts from each bone type were seeded in 
24 well plates (passage 1) at a density of 20,000 cells/well 
(triplicates per patient) were maintained in basal media until 
confluent. At confluence, conditioned media were collected 
(and monolayers lysed for RNA collection, as indicated 
above). VEGF165 concentration was measured by enzyme 
linked immunosorbent assay using the VEGF165 antibody 
pair kit (Novex, Invitrogen) according to manufacturer’s 
instructions. In order to maximise yield of data from these 
cells, VEGF-A165 concentration in osteoblast-conditioned 
medium was normalised to total RNA content measured 
by nanodrop spectroscopy (Clarkin et al., 2011); RNA was 
also used in qPCR analyses.
Statistical Analysis
Triplicate cultures were evaluated within each end point 
assay for statistical analysis. Therefore, in each case 
triplicate technical replicates for each endpoint assay were 
pooled and averaged to eliminate pseudo empowerment 
of data before statistical testing. Respective data from 
each patient were treated as independent samples and 
comparisons between osteoblasts from each bone type 
within each patient group made using Friedman test since 
the data violated Gaussian distribution (visual inspection 
of histograms). Post hoc Dunn’s multiple comparison 
tests were employed for multiple comparisons. Unpaired 
comparisons between patient groups (OA vs. OP), for 
osteoblasts from each bone type, were performed using 
Mann-Whitney U test since the data also violated normality 
rules and were unpaired. p values of less than 0.05 were 
considered significant. In addition, principal components 
analysis (PCA) (Poulet et al., 2014; Ringner, 2008), a 
dimension reduction technique, was used to summarise 16 
correlated measurements (corresponding to all individual 
end-point targets measured) into a few uncorrelated 
principal components (PC) across both patient groups and 
bone types. A linear mixed effects model was used to assess 
osteoblast differences between bone types and between 
patient groups while accounting for repeated measures 
from the same patient, and Fisher’s least significant 
difference was adopted for post-hoc comparison. PCA and 
linear mixed model analyses were carried out using IBM-
SPSS version 20. All other statistical tests were carried out 
using Prism Graphpad version 6.0f for Mac, (GraphPad 
Software, La Jolla California USA, www.graphpad.com).
Results
Osteoblasts from subchondral and cortical bone 
types proliferate more rapidly than those derived 
from trabecular bone
Following collagenase digestion, bone chips were devoid of 
adherent marrow, and cells emerged from explants within 
10-14 days of culture. The number of days taken for such 
cell outgrowth to reach 85 % confluence was recorded and 
revealed markedly different rates of outgrowth in samples 
from different bone types (Fig. 2a), with subchondral 
and cortical bone osteoblasts from OA patients showing 
similar growth, which significantly exceeded rates from 
trabecular bone by ~ 10 % (p < 0.01) and ~ 12 % (p < 0.01), 
respectively (Fig. 2a). A tendency for such superior growth 
was also evident in osteoblasts from OP patients, where 
subchondral and cortical bone osteoblasts significantly 
exceeded growth seen in trabecular osteoblasts only more 
markedly (by 63 %, p < 0.01; 70 %, p < 0.01, respectively 
(Fig. 2a)); outgrowth from subchondral and cortical bone 
did not differ significantly. These data show that bone 
type-related differences in rate of growth are retained, 
despite markedly divergent (p < 0.01) rates in OP and 
OA samples. Similar bone type-related differences in cell 
outgrowth rates, albeit 50 % faster, were also apparent in 
cells derived from a normal patient (Fig. 9a).
 In order to validate these relationships and to control 
for any bulk cellularity differences between explants, 
osteoblasts derived from each bone type were seeded 
at 2,000 cells/well and cell numbers measured after 10 
days. This confirmed growth was similar in cortical and 
subchondral bone osteoblasts and that both exceeded 
growth of trabecular-derived cells by 25 % (p < 0.01) and 
43 % (p < 0.01) in OA, and by 180 % (p < 0.01) and 175 % 
(p < 0.01) in OP patients (Fig. 2b). These bone type-related 
differences in growth rate were preserved, even though 
osteoblasts in all three types of bone from OA patients 
showed significantly faster growth compared to OP patients 
(by 57 %, 75 % and 86 % in subchondral, trabecular and 
cortical bone types (p ≤ 0.05, 0.001 and 0.01), respectively; 
Fig. 2b). Similar bone type-related trends were found in 
osteoblasts in the bone samples from the normal patient 
(Fig. 9b).
RUNX2 and SP7 mRNA levels are greater in 
osteoblasts from trabecular than subchondral and 
cortical bone types
The different growth patterns in cells derived from distinct 
bone types, led us to also examine basal osteogenic gene 
expression by qPCR. We found that RUNX2 mRNA, the 
early osteoblastic marker was significantly elevated in 
osteoblasts from trabecular compared to subchondral and 
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cortical bone types obtained from both OA (by 43 %, 
p < 0.01 and 72 %, p < 0.001 respectively) and OP patients 
(by 41 %, p < 0.01 and 83 %, p < 0.001, respectively) (Fig. 
3a,b). These studies also showed that RUNX2 mRNA levels 
in subchondral-derived osteoblasts were greater than in 
osteoblasts from cortical bone from both OA (by 41 %, 
p < 0.01) and OP patients (by 32 %, p < 0.01).
 Examination of mRNA levels of SP7, a RUNX2 
downstream target, also showed greater expression in 
trabecular- than in subchondral- (30 %, p < 0.001) and 
cortical-derived (67 %, p < 0.001) osteoblasts from 
OA patients (Fig. 3c). Osteoblasts from these different 
bone types also showed similar, albeit more marked 
differences when taken from OP patients (50 % and 83 % 
greater in trabecular osteoblasts compared to cortical 
and subchondral osteoblasts) (Fig. 3d). OP osteoblasts 
exhibited lesser RUNX-2 and SP-7 expression in all 
osteoblasts compared to OA osteoblasts (p < 0.01). These 
data illustrate that osteoblasts from both OA and OP 
show conserved, statistically divergent RUNX2 and SP7 
mRNA levels in different bone types, and that the ratio of 
RUNX2:SP7 were not significantly different in osteoblasts 
of the different bone types from each. Preliminary data 
from osteoblasts from normal bone exhibited similar 
bone type-related differences in RUNX2 and SP7 mRNA 
expression levels (Fig. 9c,d); exceeded those found in OA 
and OP samples.
TNAP activity is enriched in trabecular human 
osteoblasts
TNAP activity is a marker used to evaluate osteogenic 
activity. The divergent bone type-related RUNX2 and 
SP7 mRNA expression prompted an evaluation of TNAP 
activity in cells from each of the three bone types under 
basal, otherwise unstimulated (Fig. 4a,c) and osteogenic 
conditions (Fig. 4b,d). This showed that osteoblasts from 
trabecular bone type expressed greater TNAP activity 
under basal conditions (21 %, p < 0.05; and 52 %, 
p < 0.01) compared to subchondral and cortical types 
from OA patients. In OP patients, trabecular osteoblasts 
again showed greater TNAP activity compared to other 
bone types (30 %, not significant and 66 %, p < 0.01, 
respectively. TNAP activity in osteoblasts from each bone 
type in from OA always exceeded OP samples (p < 0.01).
 Bone type-related differential basal TNAP activities led 
us to examine differences under basal and osteogenically 
stimulated conditions. These data showed increases in 
TNAP activity in osteoblasts from all bone types in both 
OA and OP patients, with more marked increases in 
osteoblasts from subchondral and trabecular bone types. 
These increases did not, however, mask the more marked 
differences in TNAP activity in osteoblasts from each of 
the three bone types, with those from trabecular origins 
retaining the highest and those from cortical origins 
lowest TNAP activity in both OA and OP groups. Induced 
Fig. 2. Human osteoblasts from subchondral (SC), trabecular (TRB) and cortical (C) bone types form OA (n = 5 
donors) (dark blue boxes) and OP (n = 4 donors) (light blue boxes) exhibit modified growth characteristics. (a) 
Rate of OB growth from SC, TRB and C types of bone explant (to 85 % confluence). (b): OB cell growth from SC, 
TRB and C bone types over 10 days measured by crystal violet staining and DAPI nuclear counting. Results are 
expressed as the mean and 95 % CI (Confidence Intervals). *, ** or *** indicates p-values less than 0.05, 0.01 or 
0.001 respectively compared between osteoblast types. Comparisons between OA and OP for each osteoblast type 
resulted in p-values less than 0.01.
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differentiation did, however, mask the differences apparent 
between subchondral and trabecular bone types. We also 
measured ALP mRNA levels in cells from each bone type 
at a range of time-points, post-confluence which revealed 
greatest TNAP mRNA levels in trabecular and lowest 
levels in cortical bone osteoblasts, in both OP and OA 
patients (Table 2). They also show that TNAP mRNA 
levels do not change significantly from 24 h to 7 and 14 
days post-confluence. Comparing osteoblasts from each 
bone type showed that TNAP mRNA expression levels 
were significantly lower in cells from OP compared to 
OA patients (p < 0.01). Data from osteoblasts derived 
from the single ‘normal’ patient also exhibited these bone 
type-related differences in ALP activity under both basal 
and osteogenically stimulated conditions (Fig. 9e,f).
Fig. 3. Osteogenic gene expression in subchondral (SC), trabecular (TRB) and cortical (C) osteoblasts derived from 
OA (n = 5 donors) (dark blue boxes) and OP (n = 4 donors) (light blue boxes). RUNX2 (a, b) and SP7 (c, d) osteogenic 
mRNA expression levels measured by qPCR. Results are expressed as relative mean and 95 % CI. * and ** indicates 
p-values less than 0.05 and 0.01 respectively compared between osteoblast types. Comparisons between OA and OP 
for each osteoblast type resulted in p-values less than 0.01.
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Table 2. TNAP mRNA expression over 24 h, 7 d and 14 d in subchondral (SC), trabecular 
(TRB) and cortical (C) osteoblasts derived from OA (n = 5 donors) and OP (n = 4 donors) 
measured by qPCR. Results are expressed as relative mean ± SEM. a, b indicates p-values 
less than 0.05 when SC and C compared to TRB respectively. Comparisons between SC 
and C are labelled with c indicating p < 0.05. Comparisons between OA and OP for each 
osteoblast type resulted in p-values less than 0.01.
OA 24 h 7 days 14 days
SC 0.03559 ± 0.001412 0.04083 ± 0.0013 0.03684 ± 0.0015
TRB 0.05606a,b ± 0.004206 0.05978a,b ± 0.0035 0.05802a,b ± 0.0044
C 0.02009c ± 0.00243 0.023c ± 0.0028 0.0208c ± 0.0025
OP 24 h 7 days 14 days
SC 0.02279 ± 0.00113 0.02233 ± 0.0017 0.02131 ± 0.0008
TRB 0.0323a,b ± 0.000796 0.03191a,b ± 0.03191 0.03284a,b ± 0.0013
C 0.01221c ± 0.000782 0.01413c ± 0.0009 0.01623c ± 0.0027
Fig. 4. TNAP in subchondral (SC), trabecular (TRB) and cortical (C) osteoblasts from form OA (n = 5 donors) (dark 
blue boxes) and OP (n = 4 donors) (light blue boxes) under basal and induced osteogenic conditions. Panel a: TNAP 
activity in OA and OP cells under basal conditions. Panel b: TNAP activity after osteogenic stimulation. TNAP was 
measured using p-nitro-phenyl phosphate as a substrate and normalised to total cellular lysate protein content. Results 
are expressed as the mean and 95 % CI. *, ** or *** indicates p-values less than 0.05, 0.01 or 0.001 respectively 
compared between osteoblast types. Comparisons between OA and OP for each osteoblast type resulted in p-values 
less than 0.01. Panel c, d: Representative images of fixed subchondral (SC), trabecular (TRB) and cortical (C) 
osteoblasts form OA (n = 5 donors) and OP (n = 4 donors). TNAP activity was assessed as described in the methods 
by the hydrolysis of naphthol AS-TR and fast blue precipitate under basal and osteogenic conditions.
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Differential expression of maturation and bone 
matrix mineralisation genes in osteoblasts from 
different bone types
To evaluate if mRNA transcripts for factors involved in 
controlling intrinsic bone cell maturation- capacity differed 
in the three bone cell types, we measured BSP-II and 
BGLAP expression levels. In OA patients, we found that 
BSP-II mRNA levels were higher in trabecular- compared 
to subchondral-derived osteoblasts, which in turn were 
greater than in cortical osteoblasts (by 43 %, p < 0.05 and 
67 %, p < 0.05, respectively) (Fig. 5a). Osteoblasts from 
OP patients also showed these bone type-related trends in 
BSP-II mRNA levels but were significantly lower than in 
osteoblasts from OA patients (p < 0.01) (Fig. 5b).
 BGLAP mRNA levels were, however, higher in 
subchondral bone osteoblasts then trabecular (31 %, 
p < 0.05) and cortical bone types (56 %, p < 0.05) in OA 
patients (Fig. 5c). In contrast, in the OP patient group, 
trabecular osteoblasts exhibited the highest BGLAP 
mRNA levels compared to subchondral osteoblasts 
(35 %, p < 0.05) and levels in the latter further exceeded 
levels observed in cortical osteoblasts (73 %, p < 0.05). 
Subchondral osteoblasts exhibited greater BGLAP mRNA 
levels than cortical osteoblast in OP patient group, although 
not significantly (Fig. 5d). It was noted that osteoblasts 
from OP patients showed broadly similar patterns of BSP-II 
mRNA expression but that BGLAP levels were markedly 
lower in all bone types in OP patients than corresponding 
Fig. 5. Osteoblast maturation-related gene expression in subchondral (SC), trabecular (TRB) and cortical (C) osteoblasts 
derived from form OA (n = 5 donors) (dark blue boxes) and OP (n = 4 donors) (light blue boxes). BSP-II and BGLAP 
mRNA expression as the mean relative to the index of β2-microglobulin: 18s rRNA in arbitrary units and 95 % CI. 
* and ** indicates p-values less than 0.05 and 0.01 respectively compared between osteoblast types. Comparisons 
between OA and OP for each osteoblast type resulted in p-values less than 0.01 
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cells in the OA group (p < 0.01). Our preliminary studies 
using ‘normal’ bone samples showed that greatest BSP-
II and BGLAP mRNA levels were also observed in 
trabecular osteoblasts from this patient (Fig. 9g,h). These 
results illustrate bone type-related differences in markers 
involved in matrix synthesis and mineralisation and broad 
conservation of these patterns in distinct patient groups.
Subchondral and cortical human osteoblasts have 
decreased potential to stimulate osteoclastogenesis
Having found that human osteoblasts exhibit characteristic 
growth/osteogenic differentiation behaviour in distinct 
bone types which is conserved across both OA and OP 
patient groups, we sought to establish by measuring 
levels of TNFRSF11B and TNFSF11 mRNA, whether they 
might also exhibit divergent capacity to exert a paracrine 
influence on osteoclastogenesis. RANKL is expressed 
in osteoblasts and stimulates osteoclast formation and 
differentiation, while OPG is a RANKL decoy receptor 
also produced in osteoblasts (Atkins et al., 2003; Udagawa 
et al., 1999). Thus, TNFRSF11B /TNFSF11 ratios are often 
used as an index of osteoclastogenic potential. Our studies 
revealed virtually identical bone type-related differences in 
TNFRSF11B, TNFSF11 and TNFRSF11B /TNFSF11 ratios 
Fig. 6. TNFRSF11B / TNFSF11 mRNA 
expression levels in subchondral (SC), 
trabecular (TRB) and cortical (C) 
osteoblasts derived from form OA 
(n = 5 donors) (dark blue boxes) and 
OP (n = 4 donors) (light blue boxes). 
TNFRSF11B (a, b) and TNFSF11 (c, 
d) mRNA expression are expressed 
as the mean expression relative to 
the index of β2-microglobulin: 18s 
rRNA in arbitrary units and 95 % CI. 
Ratio of TNFRSF11B and TNFSF11 
mRNA expression is expressed as the 
mean expression relative to the index 
of β2-microglobulin: 18s rRNA in 
arbitrary units and 95 % CI. * and ** 
indicates p-values less than 0.05 and 
0.01 respectively compared between 
osteoblast types. Comparisons between 
OA and OP for each osteoblast type 
resulted in p-values less than 0.01.
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in OA and OP groups. Thus, TNFRSF11B mRNA levels 
were significantly higher in osteoblasts with subchondral 
and cortical bone origins compared to trabecular 
counterparts; TNFRSF11B mRNA levels in each bone type 
were also higher in OA compared to OP (p < 0.01) (Fig. 
6a,b). In contrast, TNFSF11 mRNA levels were greater in 
trabecular type osteoblasts than in subchondral (p < 0.05) 
and cortical osteoblasts in both OA and OP patients (Fig. 
6c,d). TNFSF11 mRNA expression was higher in all sites 
in OA compared to OP osteoblasts (p < 0.01). Calculating 
TNFRSF11B /TNFSF11 ratios to determine a remodelling 
‘index’ demonstrated that subchondral and cortical bone 
osteoblasts in both patient groups were equivalent, yet were 
consistently higher than in osteoblasts with trabecular bone 
origins in both OA and OP patients (p < 0.05) (Fig. 6e,f). 
Osteoblasts from normal bone showed some deviation from 
this trend, with greater ratios in subchondral osteoblasts 
than in cortical, and least in trabecular bone osteoblasts 
(Fig. 9i-k).
Subchondral bone osteoblasts exhibit greatest 
VEGF-A mRNA expression and VEGF-A165 release
Osteoblast VEGF-A165 production is critical for coupling 
osteoblast and endothelial cell behaviour (Clarkin et al., 
2008a; Clarkin and Olsen, 2010) and exerts a vital role 
in promoting osteogenesis in vivo (Liu et al., 2012). We 
therefore measured VEGF-A mRNA expression levels and 
VEGF-A165 protein release by osteoblasts. Subchondral-
derived osteoblasts expressed highest VEGF-A mRNA 
levels in both OA and OP groups; greater by 48 % (p < 0.05) 
and 68 % (p < 0.05%) in OA, and by 21 % (p < 0.05) and 
30 % (p < 0.05) compared to trabecular and cortical bone 
osteoblasts in OP, respectively (Fig. 7a,b). VEGF-A165 
protein levels in the medium conditioned by osteoblasts 
from different bone type origins followed similar patterns, 
with subchondral types consistently releasing highest levels 
in OA group (Fig. 7c). Subchondral-derived osteoblasts 
from OP patients demonstrated greatest VEGF-A165 release 
and least from trabecular bone osteoblasts (Fig. 7d). Our 
Fig. 7. VEGF-A mRNA levels and 
protein release in subchondral 
(SC), trabecular (TRB) and 
cortical (C) osteoblasts derived 
from form OA (n = 5 donors) 
(dark blue boxes) and OP (n = 4 
donors) (light blue boxes). 
VEGF-A mRNA expressed as 
the mean expression relative to 
the index of β2-microglobulin: 
18s rRNA in arbitrary units and 
95 % CI (a, b). VEGF-A protein 
release as mean ng protein/µg 
total RNA and 95 % CI (c, d). 
* and ** indicates p-values less 
than 0.05 and 0.01 respectively 
compared between osteoblast 
types. Comparisons between 
OA and OP for each osteoblast 
type resulted in p-values less 
than 0.01.
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pilot studies using osteoblasts from a single set of normal 
bone samples showed that these osteoblasts produced (Fig. 
9l,m) levels of VEGF-A165 release that was similar to OA 
(greatest in subchondral bone osteoblasts) and greater than 
in osteoblasts, from all three bone-types, in the OP group.
Principal component analysis
PCA is used to identify the main directions in which a 
dataset varies; the first PC accounts for as much variability 
in the entire data as possible, and each succeeding 
component accounts, in turn, for the highest variance 
possible that is unrelated to any preceding component. 
To better demonstrate significance in our data, we have 
therefore applied PCA to the entire data-set (16 variables). 
This discloses 2 components that explain 56 % and 29 % of 
all variation in the data. The component loading (Table 3) 
shows that the first component correlated most with TNAP 
mRNA and activity, VEGF-A mRNA and release levels, 
RUNX2, SP7, BSP-II and BGLAP mRNA levels and less 
contribution from TNFRSF11B, TNFSF11, TNFRSF11B/
TNFSF11 ratio and cell number (these 3 parameters were 
more correlated to component 2). For the first component 
the patterns between the OA and OP groups across bone 
types are similar, however, the difference between OA 
subchondral and trabecular osteoblasts compared to cortical 
osteoblasts was much greater than in the counterpart 
osteoblasts from the OP group (p < 0.0001 for interactions 
between bone types and patient groups) (Figure 8a). For 
the second component, differences exist between OA and 
OP groups (p < 0.0001) and osteoblasts from trabecular 
type bone are different from both subchondral and cortical 
osteoblasts (p < 0.0001 for both comparisons), however 
no significant differences were observed between the 
subchondral and cortical osteoblasts in both patient groups 
(p = 0.078) (Figure 8b).
Discussion
Little consideration has previously been given to the 
exact origin of cells used for in vitro characterisation of 
osteoblast behaviour or those that are used in comparing 
osteoblasts from distinct disease states. Our study is the 
first to compare the behaviour of osteoblasts derived 
from structurally distinct bone compartments, namely 
the subchondral, trabecular and cortical bone types. Our 
comparison of osteoblasts derived from these three bone 
types from singular skeletal vicinity within the same patient 
adds strength to the study, as does their examination in 
Fig. 8. Box plots illustrating PC1(a) 
and PC2(b) (summarising the 16 
parameters measured) demonstrating 
the similarities and differences 
between OA (n = 5 donors) (dark 
blue boxes) and OP (n = 4 donors) 
(light blue boxes) and the three 
respective bone types.
Table 3. Table illustrating the ‘component loading matrix’ 
for the 16 variables tested. The values for component 
loading are analogous to correlation coefficients.
Component matrix
Components
PC1 PC2
TNAP activity (OM+) 0.976 0.149
Runx-2 mRNA 0.925 -0.018
TNAP activity basal 0.924 -0.246
TNAP mRNA 7 days 0.912 -0.308
BGLAP mRNA 0.898 0.261
TNAP mRNA 24 hours 0.866 -0.402
TNAP mRNA 14days 0.783 -0.526
TNFRSF11B mRNA 0.776 -0.531
VEGF-A release 0.760 0.583
VEGF-A mRNA 0.748 0.366
SP7 mRNA -0.666 -0.615
BSP-II mRNA 0.575 -0.302
TNFRSF11B/TNFSF11 mRNA ratio -0.224 0.939
TNFSF11 mRNA 0.244 0.925
Cell Numbers 0.424 0.824
Component
Extraction Sums of Squared Loadings
Total % of Variance Cumulative %
PC1 8.468 56.456 56.456
PC2 4.328 28.855 85.311
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Fig. 9. Normal subchondral (SC), trabecular (TRB) and cortical (C) Human osteoblasts from a single patient exhibit modified growth 
characteristics. Panel a: rate of OB growth from specific types of bone explant (to 85 % confluence). Panel b: OB cell growth from 
different bone types over 10 days measured by crystal violet staining and DAPI nuclear counting. Results are expressed as mean and 
95 % CI. Panel c, d: Osteogenic gene expression in osteoblast derived from different bone types in normal human patients. RUNX-2 
and SP-7, mRNA expression levels expressed as the mean expression relative to the index of β2-microglobulin: 18s rRNA in arbitrary 
units and 95 % CI. Panel e, f: Alkaline phosphatase activity in normal human osteoblasts from diverse bone types under basal and 
induced osteogenic conditions measured by quantitation of alkaline phosphatase activity. Representative images of ALP activity 
by staining with fast blue in human osteoblasts under basal and osteogenic conditions are presented beneath. Panel g, h: Osteoblast 
maturation-related gene expression in osteoblast derived from different bone types in normal human patients. BSP-II and BGLAP 
mRNA expression levels expressed as the mean expression relative to the index of β2-microglobulin: 18s rRNA in arbitrary units 
and 95 % CI. Panel i, j, k: TNFRSF11B / TNFSF11 mRNA expression levels expressed as the mean expression relative to the index 
of β2-microglobulin: 18s rRNA in arbitrary units and 95 % CI. Panel l, m: VEGF-A mRNA levels and protein release in osteoblasts 
derived from different bone types in normal human patient samples. Results are expressed as mean and 95 % CI. * and ** indicates 
p-values less than 0.05 and 0.01 respectively compared between osteoblast types.
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both OA and OP patient groups. We show specific bone 
type-related differences in growth, differentiation capacity 
and angiogenic potential of isolated osteoblasts maintained 
in vitro as well as a preservation of many such bone 
type-related differences in bone from both OA and OP 
patient groups. We find that osteoblasts from trabecular 
bone consistently show slower proliferation, but higher 
RUNX2, SP7 and BSP-II mRNA levels, TNAP mRNA and 
protein activity, and lower TNFRSF11B:TNFSF11 mRNA 
ratios compared to those from subchondral and cortical 
bone. Another consistent bone type-related difference are 
the higher levels of VEGF-A mRNA and protein release 
by subchondral osteoblasts, implying more intimate 
vascular relationships for this bone type. Bone type-related 
behaviours were not, however conserved in OP and OA 
for all markers, with highest BGLAP mRNA levels in 
subchondral osteoblasts in OA and in trabecular osteoblasts 
in OP samples. Our data support inherent distinction in 
human osteoblasts from different bone types, likely due 
to positional or cellular progenitor origins and highlight 
the need to carefully select bone types when comparing 
osteoblasts in specific disease states.
 Use of osteoblasts derived by primary outgrowth 
from bone samples is a vital component in bone biology 
studies (Czekanska et al., 2012). The method is most 
broadly applied to isolate osteoblasts from non-diseased 
or from neonatal murine bone tissues, which multiply to 
achieve outgrowth rapidly. Cells derived by outgrowth 
or by enzyme digestion are heterogeneous, consisting 
predominantly of early osteoblasts that show accelerated 
maturation (with matrix formation, mineralisation 
and osteogenic markers) in response to exogenous 
glucocorticoids, vitamin D or bone morphogenic proteins 
(Aubin et al., 1995; Beresford et al., 1993; Declercq et 
al., 2004; Lian and Stein, 1995; Liu et al., 1994; Liu et 
al., 1997; Siggelkow et al., 1999; Wong et al., 1990). 
Attainment of osteoblast confluence is significantly slower 
from the aged and diseased human bone samples used 
herein, than in other systems (Czekanska et al., 2012; 
Perinpanayagam et al., 2001; Siggelkow et al., 1999), 
yet is nonetheless comparable with outgrowth kinetics 
described previously in similar aged human bone samples 
(Couchourel et al., 2009; Couchourel D and Delalandre 
A, 2008; Hilal et al., 1998; Hilal et al., 2001; Massicotte 
et al., 2002; Tat et al., 2008). It is therefore striking and 
somewhat discordant with popular dogma (Dodds et al., 
1989; Dodds et al., 1990; Varanasi et al., 2010) that we 
find initial osteoblast explant outgrowth to be slower in 
trabecular than in subchondral or cortical type bone. This 
bone type-related difference is unlikely due to a common 
underpinning disease mechanism as it is found in both 
OA and OP samples and in the samples from the single 
normal patient. While we cannot rule out whether these 
differences might additionally involve differential rates of 
apoptosis, our examination of growth differences, using 
direct cell counting and crystal violet staining of adherent 
viable cells after seeding at identical cell densities (Fig. 
1b), demonstrate consistent trends in relative growth in 
the different bone types in OA and OP samples. These 
latter studies, where cell numbers were initially matched 
in cultures from all three bone types make it unlikely that 
divergent growth rates are due to inherent differences in 
bulk cellularity of the samples of these bone types with 
differing macrostructures, as remarkably similar inferiority 
in osteoblast growth is observed in trabecular-derived 
cells. Our findings are therefore consistent with the notion 
that primary osteoblasts derived by outgrowth from bone 
explants may not always be homologous and that their 
behaviour relies on functional and structural differences 
of their in vivo bone type origins.
 These bone type-related cell differences may impact 
on physiological behaviour of osteoblasts in situ and 
consideration of bone’s anabolic response to loading is 
perhaps particularly pertinent. It has for example been 
reported that oestrogen receptors appear to serve different 
roles in cortical and cancellous bone responses to loading in 
female and male mice (Saxon et al., 2012). We and others 
have also reported dissimilar in vivo loading responses 
in cortical and trabecular bone with ageing (De Souza et 
al., 2005; Willie et al., 2013). However, as these studies 
cannot calibrate for load-engendered strain in trabecular 
compartments it remains impossible to know whether 
these discrepant responses are due to differing inherent 
sensitivity to the load stimulus or instead reflect different 
levels of strain exposure. Comparison of several early 
responses to identical strains have, however, reported 
divergent in vitro behaviour in osteoblasts derived from 
calvaria and ulna, suggesting that inherent differences in 
strain sensitivity may exist (Rawlinson et al., 1995). More 
exploration is clearly required in order to establish whether 
bone type-related cell behaviours we describe, underpin 
differences in how bone compartments respond to anabolic 
stimuli in the physiological context.
 There are several possible explanations for these 
inherent bone type-related differences in growth dynamics. 
Trabecular, cortical and subchondral bone clearly provide 
divergent topographies. Our studies do not allow us to 
estimate whether divergent in vivo architectures exert 
an influence on the osteoblasts derived, but ‘compact’ 
morphology of cortical and subchondral bone appears to 
endow greater proliferative capacity. If so, the underpinning 
mechanisms are retained even upon in vitro sub-seeding. 
Alternatively, trabecular-derived osteoblasts may reach a 
senescent state sooner, due to inherent differences in their 
‘Hayflick limit’ (the number of times a cell population will 
divide until cell division is arrested; Hayflick, 1965). This 
might also explain the relative deficiency in osteoblasts 
derived from OP versus OA patients (evident in each of 
the three bone types) and also the relative exuberance 
of growth in osteoblasts derived from each of the bone 
types from the normal patient. This is intriguing because 
it indicates that regardless of the bone type sampled, 
OP osteoblasts exhibit a relative deficit in cell growth 
compared with OA (or the single normal samples), 
suggesting that this may reflect a widespread underpinning 
OP disease mechanism. Chronological ageing is also 
known to increase cellular senescence (Wagner et al., 2009) 
and others have shown that osteoblast growth declines with 
age in primary bone cells and stromal cells (Lajeunesse, 
2002; Quarto et al., 1995; Zhang et al., 2008). Our data are 
also in line with studies by Giner et al. (Giner et al., 2009) 
showing that osteoblasts derived from OP patients exhibit 
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slower proliferation than those from OA patients and 
consistent with another study demonstrating their deficient 
attachment to tissue culture plastic when compared in 
vitro (Perinpanayagam et al., 2001). Such patient-related 
differences do not however explain the consistent bone 
type-related divergence in growth exhibited by osteoblasts 
based upon their trabecular, subchondral and cortical 
bone origins. They are, however, in some agreement with 
additional studies demonstrating osteoblast heterogeneity 
in bone tissue (Dodds et al., 1989; Dodds et al., 1990) 
and bone cells extracted from different bone types and 
anatomical locations (Mcduffee et al., 2006; Ninomiya et 
al., 1990).
 These positional or progenitor origins may also explain 
the bone type-related differences in differentiation potential 
we observed. We found that osteoblasts with trabecular 
origins exhibited greater RUNX2, SP7 and BSP-II mRNA 
levels and TNAP activity than subchondral or cortical 
type osteoblasts. Our study also evaluates the behaviour 
of subchondral-derived osteoblasts. Akin to trabecular 
bone osteoblasts, osteoblasts from subchondral type 
bone exhibited higher RUNX2, SP7 and BSP-II mRNA 
expression than cortical osteoblasts, but in contrast also 
displayed correspondingly high growth rates. Although 
expressed by other cells types where their functions remain 
incompletely defined (Choi et al., 2001; Jeong et al., 
2008), RUNX2 and SP7 are considered master regulators 
of osteoblast differentiation (Ducy et al., 1997; Hartmann, 
2009; Komori et al., 1997; Komori, 2006). Our study 
emphasises divergent RUNX2 and SP7 expression levels 
in osteoblasts from different bone types, which imply that 
subchondral osteoblasts possess greater inherent potential 
for in vitro growth and differentiation. Our data showing 
that levels of TNAP mRNA expression are maintained at 
24 h, 7 days and 14 days post confluence, support retention 
of this inherent difference in osteoblasts from divergent 
bone types. We thenceforth maintained cells for 36 days in 
basal media and OM+ media and observed that trabecular 
osteoblasts exhibited greater ALP activities under basal and 
osteogenically stimulated conditions, further emphasising 
the inherent diversity in osteoblasts from these distinct 
bone types. Indeed, they are likely consistent with studies 
revealing different differentiation capacity in bone from 
neighbouring locations within single OA patient groups 
(Hilal et al., 2001; Lavigne et al., 2005; Westacott et al., 
1997) and with recent studies describing distinct function 
and molecular properties in human haematopoietic stem 
cells in trabecular bone compartments from those located 
deeper in the marrow (Guezguez et al., 2013). Our studies 
highlight that osteoblasts from the different bone types 
showed matching disparity in both OA and OP patients. 
Furthermore, it is pertinent to stress that osteoblasts 
from OP patients exhibited a conserved deficiency in 
differentiation capacity, in each of the three bone types, 
when compared with either OA (or the single ‘normal’ 
patient); again indicating that OP may demonstrate 
systemic modification in bone cell function.
 Previous studies using bone-seeking isotopes have 
led to a general acceptance that osteoblasts of trabecular 
bone have greater metabolic activity than those of the 
cortex and that this is retained in vitro due to the larger 
surface areas from which they are derived (Varanasi et 
al., 2010). Direct measurement of ‘metabolic’ activities of 
representative enzymes of the major oxidative pathways 
have shown that the reverse, in fact, pertained (Dodds et 
al., 1989; Dodds et al., 1990). Our data make the distinction 
between osteoblast growth and capacity of cells from 
dissimilar bone types to differentiate, demonstrating that 
the enhanced osteogenic markers and TNAP activity shown 
by osteoblasts from trabecular bone types is not necessarily 
allied to more rapid increases in cell number, which are 
evident in osteoblasts from subchondral bone types. These 
findings appear consistent with those of Solchaga et al. 
(Solchaga et al., 1998) in which greater TNAP activity and 
significantly higher mineral deposition was observed in 
cells derived from marrow than periosteum of rabbit tibiae; 
it is tempting to speculate that osteoblasts from trabecular-
type bone more closely resemble the former and cortical-
type osteoblasts the latter, respectively. It may be possible 
that the data presented in this study suggest an inherent 
diversity within the progenitor cell pool in these diverse 
bone types, which would require further investigations. 
If such inherent diversity does indeed exist, our findings 
demonstrating deficient growth and differentiation capacity 
in samples from OP patients would be consistent with a 
widespread scarcity of such progenitors.
 Studies using human diseased bone samples have 
limitations. Foremost is the paucity of age/gender matched 
control samples from healthy, normal bone for comparison. 
Our efforts to redress this have generated pilot data from 
one set of normal bone samples and whilst these support 
identical bone type-related divergence in osteoblast 
behaviour, it is vital they are confirmed in multiple samples 
if more general conclusions regarding the impact of our 
findings are to be more broadly appreciated. In addition, we 
also acknowledge the possibility that primary cell culture 
cannot necessarily guarantee that all of the cells derived 
from different bone types are exactly the same. However, 
given that the method employed for primary cell isolation/
outgrowth from all three-bone types was identical, it 
is evident that the bone type-related differences in cell 
phenotype we have described highlight dissimilarities 
in their behaviour. Another limitation arises due to the 
slow growth and restricted cell numbers available from 
these samples. This restricts scope to perform analyses at 
multiple in vitro time-points and makes it unfeasible to use 
alternative methods, such as FACS analysis to quantify 
live/dead cells or surface markers. Direct observations 
during the cell growth phase nonetheless disclosed no 
obvious signs of apoptosis such as cell blebbing, shrinking 
or detachment. Another limitation is the lack of capacity to 
correlate our observations with one of the most important 
features of osteoblasts in vitro, namely their ability to 
deposit mineralised extracellular matrix. Our pilot studies 
showed that this capacity for mineralisation is highly 
compromised in osteoblasts derived from OA and OP 
bone samples, with little mineralisation even after 56 days 
(data not shown; compared with overt mineralisation by 
36 days in normal human cultures). This deficiency in 
mineralisation was greater in OP patient cells compared 
to OA. Our findings are in agreement with studies by 
Siggelkow and colleagues (Siggelkow et al., 1999) 
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and those showing that mineralisation in OA derived 
subchondral osteoblasts is compromised compared to 
those from normal (Couchourel et al., 2009). This disease-
related lack of mineralisation may be compounded by the 
advanced age of patients acting as bone donors in this study, 
and with respect to OP osteoblasts it may be a consequence 
of the disease and further elucidation of the underpinning 
mechanisms would be required.
 Somewhat surprisingly the only significant deviation 
from the consistent bone type-related osteoblast 
differentiation markers seen in OP and OA groups was the 
elevated BGLAP mRNA levels in subchondral osteoblasts 
in the OA patients and in the trabecular osteoblasts of 
patients with OP. The latter is completely in line with the 
relatively elevated levels of all other markers of osteoblast 
differentiation measured in the trabecular osteoblast of 
OP patients, but the former raises an interesting paradox 
particular to OA patients, suggesting that this is more 
likely disease-specific. This is supported by previous 
studies demonstrating elevated BGLAP mRNA levels 
in subchondral bone regions in OA patients, which is 
further exaggerated in sclerotic (vs. non sclerotic) regions 
(Sanchez et al., 2008). It is likely that application of 
similar approaches, restricting the study of osteoblast 
behaviour in disease to only direct comparison within 
single, specific bone types, is likely to reduce experimental 
inhomogeneity and speed identification of underpinning 
disease mechanisms.
 This is perhaps accentuated by studies distinguishing 
two separate groups of subchondral bone OA osteoblasts: 
‘low’ – which resemble normal osteoblasts – and ‘high’ 
osteoblasts with corresponding prostaglandin E2 and 
IL-6 levels (Hilal et al., 2001; Massicotte et al., 2002). 
More recent data indicate a close relationship between 
these OA subchondral osteoblasts and the OPG/RANK/
RANKL system, linking to structural bone changes in 
OA (Tat et al., 2008; Tat et al., 2009). It was found that 
‘low’ osteoblasts express depleted TNFRSF11B, but high 
TNFSF11 levels, whereas ‘high’ OA osteoblasts express the 
reverse (Tat et al., 2008). Consideration of these findings 
in the light of our own, which shows that trabecular type 
osteoblasts express lower TNFRSF11B:TNFSF11 ratios 
compared to subchondral and cortical osteoblasts, implies 
that ‘low’ – more normal – subchondral osteoblasts show 
greater resemblance with those derived from trabecular 
compartments. It is also pertinent that lower osteoblast 
TNFRSF11B:TNFSF11 ratios (observed in OP osteoblasts) 
are likely to promote bone resorption assuming correlative 
post-translational trends, suggesting that such remodelling 
activities will predominate in trabecular type bone and 
will also be more marked in bone from OP than OA (and 
normal) patient groups. RANKL and OPG protein levels 
were not measured herein, however previous studies 
have demonstrated close correlation of osteogenic protein 
expression to mRNA levels (Born et al., 2009; Deyama et 
al., 2000; Hofbauer et al., 1999; Rickard et al., 1996; Shea 
et al., 2000).
 The possibility that osteoblasts from subchondral, 
cortical and trabecular bone types might exert differential 
recruitment of osteoclasts from the vasculature, prompted 
studies into their potential capacity to also control 
angiogenesis. Osteogenesis and angiogenesis are closely 
related processes that are intimately linked during bone 
development, growth, remodelling and fracture repair 
(Clarkin et al., 2008a; Clarkin and Gerstenfeld, 2013; 
Clarkin and Olsen, 2010). VEGF has emerged as an 
essential component promoting this relationship (Fazzalari, 
2011; Hankenson et al., 2011; Marsell and Einhorn, 2011) 
and its intracellular effects have recently been shown to 
promote osteogenesis at the expense of adipogenesis (Liu 
et al., 2012). We therefore measured their relative mRNA 
levels and release of secreted VEGF (Clarkin et al., 2008a). 
This revealed a clear hierarchy in VEGF-A mRNA levels 
in OA and OP (and normal samples from a single patient) 
bone types, with highest levels in subchondral, followed 
by trabecular and cortical-derived osteoblasts; it was 
also clear that OA consistently exceeded levels in OP 
patients (and more akin to normal). These data accord with 
those of Sanchez et al. (Sanchez et al., 2008) and imply 
that osteoblasts from subchondral bone (amongst those 
examined herein) have the most intimate relationship with 
the vasculature, particularly in OA, which may contribute 
to osteochondral OA pathophysiology. The basis of the 
consistently lower bone type-matched VEGF mRNA (and 
protein) levels in OP samples is also intriguing and may 
reflect the greater susceptibility to fracture in OP than 
OA patients; this however requires further exploration. 
VEGF-A165 protein levels in conditioned media from 
osteoblasts also generally match those for mRNA 
expression, with one exception. Thus, while VEGF-A 
mRNA levels were higher in trabecular than cortical-
derived osteoblasts from OP patients, relative VEGF-A165 
protein levels were significantly lower. This suggests some 
impairment in VEGF translation or post-translational 
VEGF degradation in OP trabecular bone osteoblasts, but 
is nonetheless consistent with the altered proangiogenic 
signalling of bone reported in these patients (Burkhardt 
et al., 1987; Ding et al., 2011; Xia et al., 2012). Indeed, 
it has been shown that primary OA and OP osteoblasts 
express differential VEGF-A levels (Corrado et al., 2013), 
which are in line with our findings. The demonstration 
of elevated VEGF-A expression in metaphyseal versus 
diaphyseal periosteal locations in osteoporotic rats (Fan 
et al., 2010) further illustrates the requirement to explore 
variations in the communication by osteoblasts to the 
vasculature, which is critical for bone maintenance and 
repair, in different bones types. Since VEGF is central to 
coupling angiogenesis in bone healing, our data raise the 
intriguing possibility that osteoblasts from different bone 
types exhibit divergent potential for VEGF-mediated 
crosstalk with the vasculature, with those in subchondral 
bone having a relative advantage (Fazzalari, 2011; Report 
of a WHO study Group, 1994; Sarahrudi et al., 2009).
 Our study identifies basal differences in primary 
osteoblast behaviour that are linked to the diversity in the 
type, or category of bone. We cannot be sure that these 
bone type-related attributes are necessarily replicated at all 
other skeletal locations or are conserved in all species. They 
are, however, reinforced significantly by a preservation of 
many of these differences in the distinct OA and OP patient 
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groups (and a single set of samples from a normal patient) 
examined and this illustrates that these characteristics do 
not simply reflect disease manifestation but are rather bone 
type-related in human specimens.
Conclusion
Although the importance of our findings would be greatly 
extended if similar bone type-related behaviours were 
confirmed, with the inclusion of more replicates of normal 
human bone osteoblasts, our data support the hypothesis 
that osteoblasts in trabecular, subchondral and cortical bone 
regions of the human skeleton have inherent, programmed 
diversity in their behaviour. It is tempting to speculate 
that this may extend to definable divergence in their 
responses to soluble and mechanical extracellular cues 
and systemic factors, and that such elucidation will allow 
for specific bone type-selective regulation. This raises a 
major caveat in our study; as it is possible osteoblasts from 
these different bone types only exhibit such divergence 
in behaviour in human shoulder joint samples. This 
accentuates a need for further studies to address whether 
this paradigm is extended to other skeletal elements. It is 
also possible that the differences uncovered by our studies 
are related to the developmental origins of the osteoblasts 
in these types of bones (Rawlinson et al., 2009). Our 
studies have shown that primary osteoblasts derived from 
diverse trabecular, cortical and subchondral bone types 
from within a single anatomical location have distinctive 
growth, differentiation, remodelling and pro-angiogenic 
characteristics, which may underpin some of the divergent 
behaviour of bone at these sites. Our studies also reveal 
that osteoblasts derived from all three types of bone from 
OP patients exhibit diminished growth, differentiation 
and pro-angiogenic signalling than counterparts from OA 
patients, suggesting that such deficit may be systemic, 
rather than local. With further studies to validate these 
conclusions, this work may also provide further rationale 
for development and design of new implants that target 
specific bone types in order to avoid complications 
associated with use of long stemmed prosthesis and their 
redesign to harness greatest pro-angiogenic capacity and 
fracture healing. Further investigations are clearly required 
to explore this potential.
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Discussion with Reviewer
Reviewer I: If the outcome of this study is subsequently 
substantiated, how would this affect the use of MSCs for 
therapeutic applications?
Authors: It is possible that a more complete understanding 
of the factors governing the diversity in behaviour in 
osteoblasts from different types of bone, will better inform 
use of MSC for therapeutic applications.
 It may, for instance, allow for greater “selection” 
of particular bone cell behaviour, favouring formation 
of specific bone types at a certain location, and this 
allow better tailoring of MSC application to the clinical, 
therapeutic need. Without conducting more functional 
studies both in vitro and in vivo it is difficult, however, 
to predict how this will impact on therapeutic MSC 
applications. Our data may be an indication that MSC from 
different sites will also exhibit some diversity in genetic 
and functional signatures, possibly owing to their particular 
environmental niche. This may therefore contribute to 
greater selection being placed on the location for MSC 
harvesting.
Reviewer I: What possible mechanisms do you think are 
involved in osteoblast diversity? Is it modified by local 
niches or inherent in the development pathway?
Authors: This is an interesting question. The possible 
mechanisms involved in osteoblast diversity are yet to be 
uncovered. It is possible that both local niches and inherent 
differences in developmental origins and pathways are 
involved. If we had to make a prediction, we feel that it 
would be likely that osteoblast diversity would reflect a 
combination of both local, environmental influences and 
inherent pre-programming. Recent evidence indicating that 
at least some trabecular bone osteoblasts may be derived 
from hypertrophic chondrocytes of the growth plate might 
be interpreted as evidence that such diversity in osteoblast 
origins indeed exists (Yang L et al., 2014; Yang G et al., 
2014; Zhou et al., 2014). Without definitive identification 
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of the mechanisms and factors governing such diversity, 
however, it is not possible to pinpoint the answer to this 
fascinating question.
Reviewer II: Do the authors think that these findings would 
be the same in large species (ovine/bovine), small rodent 
species (mouse/guinea pig/rat) and in non-mammalian 
species?
Authors: We acknowledge that the impact of the differing 
human bone type-related cell attributes reported here 
would be modified if they were conserved in all species. 
Selection of both location for sampling and species would 
however need to be made carefully. Bone size would need 
to be taken into account, as obtaining sufficiently large 
samples from very small l rodents is not trivial. Rodent 
bone might also be deemed inappropriate for comparison, 
as it is predominantly primary rather than secondary. Larger 
species do not necessarily simplify this choice, as bone 
from ovine and bovine species, although macroscopically 
similar to human, can have plexiform structure, with 
combinations of woven/lamellar organisation sandwiching 
vascular plexuses (Aerssens et al., 1997; Manilay et al., 
2013; Pearce et al., 2007). Different species also exhibit 
divergent post-natal growth, modelling and remodelling 
patterns and this might also translate to differences in 
osteoblast in vitro. It is nonetheless pertinent to visit how 
any such studies might be interpreted too. Would failure 
to replicate our findings in all species necessarily diminish 
their significance to human? Would their replication in all 
species offer any explanation regarding their origins? Do/
how do bone type-related differences in cell behaviour 
impact on physiological bone responses in vivo? Can 
they be exploited to achieve targeting of one bone site 
over another? There are many further questions that 
our findings raise and whether there are similarities (or 
differences) in osteoblasts isolated from similar bone types 
in other mammalian and non-mammalian species would 
be of great interest in this regard.
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